Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Ponatinib lung squamous cell carcinoma sensitive detail...
PTEN loss AZD8186 lung squamous cell carcinoma predicted - sensitive detail...
FGFR1 amp Dovitinib lung squamous cell carcinoma no benefit detail...
PIK3CA over exp Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA E545K Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA H1047R Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA over exp Dactolisib lung squamous cell carcinoma sensitive detail...
PIK3CA E545K Dactolisib lung squamous cell carcinoma sensitive detail...
PIK3CA H1047R Dactolisib lung squamous cell carcinoma sensitive detail...
PIK3CA H1047R Alpelisib lung squamous cell carcinoma sensitive detail...
PIK3CA E545K Alpelisib lung squamous cell carcinoma sensitive detail...
PIK3CA over exp Alpelisib lung squamous cell carcinoma sensitive detail...
FGFR1 amp RO4987655 lung squamous cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung squamous cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung squamous cell carcinoma no benefit detail...
HRAS Q61L Selumetinib lung squamous cell carcinoma sensitive detail...
HRAS Q61L Buparlisib lung squamous cell carcinoma no benefit detail...
HRAS Q61L Everolimus + Selumetinib lung squamous cell carcinoma sensitive detail...
HRAS Q61L Binimetinib + Everolimus lung squamous cell carcinoma sensitive detail...
HRAS Q61L AZD8055 + Binimetinib lung squamous cell carcinoma sensitive detail...
FGFR1 amp Infigratinib lung squamous cell carcinoma sensitive detail...
PTEN negative Buparlisib lung squamous cell carcinoma sensitive detail...
FGFR1 amp AZD4547 + Buparlisib lung squamous cell carcinoma sensitive detail...
FGFR3 positive Rogaratinib lung squamous cell carcinoma predicted - sensitive detail...
FGFR1 amp AZD4547 lung squamous cell carcinoma no benefit detail...
PTEN loss Buparlisib lung squamous cell carcinoma no benefit detail...
PIK3CA amp Buparlisib lung squamous cell carcinoma no benefit detail...
PIK3CA act mut Buparlisib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA E545K PIK3CA amp Buparlisib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA E542K PIK3CA amp Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA E545K PTEN loss Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA act mut Alpelisib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA E542K PIK3CA amp Alpelisib lung squamous cell carcinoma sensitive detail...
PIK3CA E542K PTEN loss Alpelisib lung squamous cell carcinoma sensitive detail...
CDKN2A loss PIK3CA act mut Buparlisib + Palbociclib lung squamous cell carcinoma predicted - sensitive detail...
CDKN2A loss PIK3CA E545K PIK3CA amp Buparlisib + Palbociclib lung squamous cell carcinoma sensitive detail...
CDKN2A loss PIK3CA E542K PTEN loss Buparlisib + Palbociclib lung squamous cell carcinoma sensitive detail...
CDKN2A loss PIK3CA E542K PIK3CA amp Buparlisib + Palbociclib lung squamous cell carcinoma sensitive detail...
FGFR1 amp Debio 1347 lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA mutant Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA E545K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA E542K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA H1047R Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA N345K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA E453K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA G1049R Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA M1043I Taselisib lung squamous cell carcinoma no benefit detail...
CDKN2A loss Palbociclib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA mutant Capivasertib lung squamous cell carcinoma no benefit detail...
PIK3CA amp Capivasertib lung squamous cell carcinoma no benefit detail...
PTEN loss Capivasertib lung squamous cell carcinoma no benefit detail...
FGFR1 amp Carboplatin + GSK3052230 + Paclitaxel lung squamous cell carcinoma predicted - sensitive detail...
FGFR1 over exp Rogaratinib lung squamous cell carcinoma no benefit detail...
FGFR3 over exp Rogaratinib lung squamous cell carcinoma no benefit detail...
FGFR2 over exp Rogaratinib lung squamous cell carcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting USA 2
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting USA 0
NCT01741727 Phase II Depatuxizumab mafodotin A Study of ABT-414 in Subjects With Solid Tumors Completed USA | CAN 0
NCT01820325 Phase II Buparlisib Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Terminated USA | CAN 3
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed USA 0
NCT01948141 Phase II Nintedanib Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens Completed USA 0
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA 6
NCT02154490 Phase II Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA 4
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Active, not recruiting USA 1
NCT02403895 Phase II Vistusertib Paclitaxel AZD2014 and Weekly Paclitaxel in Squamous NSCLC Terminated USA 2
NCT02417701 Phase II Sapanisertib Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer Completed USA 0
NCT02443337 Phase II Necitumumab LY3023414 A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Terminated USA 0
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated USA 0
NCT02513563 Phase II Carboplatin + Paclitaxel Adavosertib AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Recruiting USA 0
NCT02536495 Phase Ib/II Docetaxel Selinexor Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer Withdrawn 0
NCT02785913 Phase II Taselisib Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Completed USA | CAN 0
NCT02785939 Phase II Palbociclib Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Completed USA 0
NCT02785952 Phase III Nivolumab Ipilimumab + Nivolumab Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting USA | CAN 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting 1
NCT02924233 Phase Ib/II Nivolumab + SYM004 Nivolumab Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Withdrawn 0
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting USA 0
NCT03157089 Phase II Afatinib + Pembrolizumab Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO) Completed USA 4
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting USA | CAN 26
NCT03212469 Phase Ib/II Durvalumab + Tremelimumab A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) Recruiting 1
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) Active, not recruiting USA | CAN 17
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Completed USA 2
NCT03261947 Phase II TAK-931 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Completed USA 1
NCT03267316 Phase Ib/II Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) Recruiting 11
NCT03377556 Phase II Talazoparib Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Completed USA | CAN 0
NCT03409614 Phase III Cemiplimab + Ipilimumab Cemiplimab Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Active, not recruiting USA 18
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Recruiting USA 1
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting USA 0
NCT03496766 Phase II Tipifarnib Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS Recruiting 1
NCT03526887 Phase II Pembrolizumab Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) Recruiting 1
NCT03574753 Phase II Telisotuzumab vedotin Lung-MAP S1400K: c-MET Positive Completed USA 0
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03823625 Phase II Ipilimumab + Nivolumab Carboplatin + Gemcitabine + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT) Recruiting 1
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting USA | CAN 2
NCT03970746 Phase Ib/II PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC Recruiting 3
NCT03975114 Phase II Durvalumab + Tremelimumab Durvalumab A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) Recruiting 1
NCT03976362 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Olaparib + Pembrolizumab A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) Active, not recruiting USA | CAN 18
NCT03976375 Phase III Lenvatinib Lenvatinib + Pembrolizumab Docetaxel Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) Recruiting USA | CAN 16
NCT04033354 Phase III Carboplatin + Nab-paclitaxel + Serplulimab Carboplatin + Nab-paclitaxel A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC Recruiting USA 1
NCT04043195 Phase Ib/II Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) Recruiting USA 0
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Active, not recruiting USA 0
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting USA 0
NCT04262856 Phase II AB154 + AB928 + GLS-010 GLS-010 AB154 + GLS-010 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) Recruiting USA | CAN 5
NCT04266730 Phase I PANDA-VAC + Pembrolizumab + Poly ICLC Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) Not yet recruiting USA 0
NCT04350463 Phase II CC-90011 + Nivolumab A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers Recruiting USA 5
NCT04357873 Phase II Pembrolizumab + Vorinostat Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) Recruiting 1
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Active, not recruiting USA 3
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Recruiting USA 1
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT04497584 Phase II Afatinib + Prednisone Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC Recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04748419 Phase Ib/II Durvalumab Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab Recruiting USA 0
NCT04758949 Phase II Nivolumab FL-101 + Nivolumab FL-101 FL-101 in Surgically Resectable Non-Small Cell Lung Cancer Recruiting USA | CAN 2
NCT04822298 Phase I AMG 160 Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer Recruiting 2
NCT04939701 Phase Ib/II ASP0739 + Pembrolizumab ASP0739 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants Recruiting USA 0
NCT04956692 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) Recruiting USA 10
NCT05127590 Phase Ib/II Pembrolizumab + RBN-2397 RBN-2397 in Combination With Pembrolizumab in Patients With SCCL Recruiting USA 2